Government clarifies stance on cost-effectiveness assessment of statin preparations

Published: 2008-05-21 07:00:00

Updated: 2008-05-21 07:00:00

The Health Insurance Review Agency said on May 16 that its assessment on the cost-effectiveness of new antihyperlipidemic agents is entirely based on scientific evidences, expressing its regret over miscommunication between government and industry.

In an information session, the HIRA said that it could not identify any significant differences in the prevention of cardiovascular disease among...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.